GSK-1070916A cas 942918-07-2

GSK1070916, also known as NMI-900 or GSK-1070916A, is an ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora kinases B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C.

Aurora Kinase Related Prodcuts:

Alisertib; Tozasertib; SP600125; Danusertib; AT9283; Hesperadin; ENMD-2076; ENMD-2076 Tartrate; MK-5108; CYC-116; CCT137690; XL228; SNS-314; SNS-314 mesylate; MK-8745

[1]. Adams ND, et al. Discovery of GSK-1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.

[2]. Hardwicke MA, et al. GSK-1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009 Jul;8(7):1808-17.